33446-21-8

Basic information

• Product Name: MDAT
• Synonyms: MDAT
• CAS NO: 33446-21-8
• Molecular Formula: C₁₁H₁₃NO₂*ClH
• Molecular Weight: 227.68736
• EINECS: -0
• Mol File: 33446-21-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 331.7 °C at 760 mmHg
• Flash Point: 169.1 °C
• Appearance: /
• Vapor Pressure: 0.000153mmHg at 25°C
• CAS DataBase Reference: MDAT(CAS DataBase Reference)
• NIST Chemistry Reference: MDAT(33446-21-8)
• EPA Substance Registry System: MDAT(33446-21-8)

Safety Data

• Hazardous Substances Data: 33446-21-8(Hazardous Substances Data)

Usage

General Description

MDAT, or 3,5-dimethyl-2,4-dimethoxyamphetamine, is a synthetic compound that falls under the category of phenethylamines. It is a hallucinogenic drug and a derivative of amphetamine. MDAT is known for its psychoactive effects, which include visual and auditory hallucinations, altered perceptions, and changes in mood. The drug is also associated with increased energy and euphoria, as well as potential negative effects such as anxiety, paranoia, and agitation. It is considered a controlled substance in many countries and is illegal to possess, produce, or distribute without proper authorization. The long-term effects of MDAT on the brain and body are not well understood, and its use is associated with various health risks and potential for addiction.

InChI:InChI=1/C11H13NO2.ClH/c12-9-2-1-7-4-10-11(14-6-13-10)5-8(7)3-9;/h4-5,9H,1-3,6,12H2;1H

Synthetic route

2-(N-benzylamino)-6,7-(methylenedioxy)-1,2,3,4-tetrahydronaphthalene hydrochloride → 6,7-(methylenedioxy)-2-aminotetralin hydrochloride (33446-21-8)

Conditions	Yield
With hydrogen; palladium on activated charcoal In ethanol under 2585.7 Torr;	100%

Relevant articles and documents

Nonneurotoxic Tetralin and Indian Analogues of 3,4-(Methylenedioxy)amphetamine (MDA)

Four cyclic analgues of the psychoactive phenethylamine derivative 3,4-(methylenedioxy)amphetamine were studied.These congeners, 5,6- and 4,5-(methylenedioxy)-2-aminoindan (3a and 4a, respectively), and 6,7- and 5,6-(methylenedioxy)-2-aminotetralin (3b and 4b, respectively) were tested for stimulus generalization in the two-lever drug-discrimination paradigm.Two groups of rats were trained to discriminate either LSD tartrate (0.08 mg/kg) from saline, or (+/-)-MDMA*HCl (1.75 mg/kg) from saline.In addition, a 2-aminoindan (5a) and 2-aminotetralin (5b) congener of the hallucinogenic amphetamine 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) were also evaluated.None of the methylenedioxy compounds substituted in LSD-trained rats, while both 3a and 3b fully substituted in MDMA-trained rats.Compounds 4a and 4b did not substitute in MDMA-trained rats.Compounds 5a and 5b did not substitute in MDMA-trained rats, although 5a substituted in LSD-trained rats, but with relatively low potency compared to its open-chain counterpart.In view of the now well-established serotonin neurotoxicity of 3,4-(methylenedioxy)amphetamine and its N-methyl homologue 1, 3a and 3b were evaluated and compared to 1 for similar toxic effects following a single acute dose of 40 mg/kg sc.Sacrifice at 1 week showed that neither 3a nor 3b depressed rat cortical or hippocampal 5-HT or 5-HIAA levels nor were the number of binding sites (Bmax) depressed for paroxetine.By contrast, and in agreement with other reports, 1 significantly depressed all three indices of neurotoxicity.These results indicate that 3a and 3b have acute behavioral pharmacology similar to 1 but that they lack similar serotonin neurotoxicity.